DiaMedica Therapeutics (DMAC) Other Non Operating Income (2018 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Other Non Operating Income of $447000.0 for Q1 2026, up 0.9% year-over-year from $443000.0 in Q1 2025, and down 16.6% quarter-over-quarter from $536000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Other Non Operating Income (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics' Other Non Operating Income history runs 9 years deep, the most recent figure standing at $447000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 0.9% year-over-year to $447000.0; the TTM figure through Mar 2026 stood at $963000.0 (up 108.44% YoY), while the FY2025 annual figure was $515000.0, changed N/A from the prior year.
- Other Non Operating Income for Q1 2026 stood at $447000.0, down from $536000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $709000.0 in Q4 2023, with the low at -$21000.0 in Q3 2025.
- The 5-year median for Other Non Operating Income is $216000.0 (2022), against an average of $252411.8.
- Peak annual rise in Other Non Operating Income reached 2721.05% in 2025, while the deepest fall reached 950.0% in 2025.
- DiaMedica Therapeutics' Other Non Operating Income stood at $216000.0 in 2022, then jumped by 228.24% to $709000.0 in 2023, then tumbled by 97.32% to $19000.0 in 2024, then soared by 2721.05% to $536000.0 in 2025, then decreased by 16.6% to $447000.0 in 2026.
- Business Quant data shows DMAC's Other Non Operating Income at $447000.0 in Q1 2026, $536000.0 in Q4 2025, and -$21000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 366,000.00 |
| Mar 31, 2026 | 447,000.00 |
| Dec 31, 2025 | 536,000.00 |
| Sep 30, 2025 | -21,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 443,000.00 |
| Dec 31, 2024 | 19,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 597,000.00 |
| Dec 31, 2023 | 709,000.00 |
| Sep 30, 2023 | 693,000.00 |
| Jun 30, 2023 | 271,000.00 |
| Mar 31, 2023 | 256,000.00 |
| Dec 31, 2022 | 216,000.00 |
| Sep 30, 2022 | 76,000.00 |
| Jun 30, 2022 | 13,000.00 |
| Mar 31, 2022 | 35,000.00 |
| Dec 31, 2021 | 346,000.00 |
| Sep 30, 2021 | -27,000.00 |